<DOC>
	<DOCNO>NCT02366312</DOCNO>
	<brief_summary>The purpose study determine well daily dose 150 mg Erivedge ( vismodegib ) reduce Keratocystic odontogenic tumor ( KCOT ) size , evaluate safety dose . Erivedge FDA-approved use adult specific type skin cancer . However , drug experimental patient KCOT .</brief_summary>
	<brief_title>A Phase 2 , Single-center , Single-arm , Open Label Trial Vismodegib Patients With Keratocystic Odontogenic Tumors</brief_title>
	<detailed_description>This single-center , interventional , single-arm , open-label , two-cohort clinical trial . A total 20 patient enrol ( 10 NBCCS-associated KCOT 10 sporadic KCOT ) period 2 year . This 3 year study patient undergo 1 year treatment 2 year post-treatment follow-up . All patient assess safety efficacy study drug GDC-0449 ( Vismodegib ) .</detailed_description>
	<mesh_term>Odontogenic Tumors</mesh_term>
	<criteria>Males female , 18 year age time informed consent form sign ; Able understand sign Informed Consent Form necessary paperwork prior initiation study procedure ; Able communicate investigator/study site personnel , understand comply study requirement , willing return specify visit appoint time ; Patients receive prior treatment KCOT diagnosis recurrent ( maxillary mandibular ) sporadic KCOT NBCCSassociated KCOT ( single multiple ) ; Diagnosis KCOT do past pathology report biopsy study site , applicable ; Willingness consent biopsy lesion , need ; Willingness delay excision target tumor site , unless evidence disease progression lack drug tolerability ; Willingness donate blood genetic testing ; For female patient childbearing potential , agreement use two acceptable method birth control , include one barrier method study 7 month discontinuation study drug ; For male female partner childbearing potential , agreement use male condom ( spermicide ) advise female partner use acceptable method birth control study 2 month discontinuation study drug ; Agreement donate blood/blood product study 7 month discontinuation study drug ; For male donate sperm product semen treatment 2 month discontinuation study drug ; Able willing swallow pill ; No malabsorption syndrome condition would interfere enteral absorption ; At least 4 week since last chemotherapy , investigational therapy , radiotherapy major surgical procedure recover first study drug administration ; KCOT measure least 1 cm one dimension pretreatment volumetric CT scan ; No clinically significant abnormality clinical laboratory assessment ; Concurrent antitumor therapy ; Completion recent antitumor therapy ( include Vismodegib ) less 4 week prior initiation treatment ( first study drug administration ) ; Uncontrolled medical illness ; Pregnancy lactation ; female patient plan become pregnant duration study 7 month posttreatment ; Inability unwillingness swallow capsule ; Any medical psychological illness condition prevent adequate consent ; History significant atherosclerotic disease , include follow : Coronary artery disease ( i.e. , myocardial infarction within past year unstable angina ) ; Documented carotid atheroma ; Known HIV infection ; Current alcohol abuse ; History resistance vismodegib ( patient previous receive vismodegib BCC clinical response exclude ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Keratocystic odontogenic tumor</keyword>
	<keyword>KCOT</keyword>
</DOC>